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Abstract
Background: Activation of NMDA receptors can induce iron movement into neurons by the small GTPase Dexras1
via the divalent metal transporter 1 (DMT1). This pathway under pathological conditions such as NMDA excitotoxicity
contributes to metal-catalyzed reactive oxygen species (ROS) generation and neuronal cell death, and yet its
physiological role is not well understood.
Results: We found that genetic and pharmacological ablation of this neuronal iron pathway in the mice increased
glutamatergic transmission. Voltage sensitive dye imaging of hippocampal slices and whole-cell patch clamping of
synaptic currents, indicated that the increase in excitability was due to synaptic modification of NMDA receptor activity
via modulation of the PKC/Src/NR2A pathway. Moreover, we identified that lysosomal iron serves as a main source for
intracellular iron signaling modulating glutamatergic excitability.
Conclusions: Our data indicates that intracellular iron is dynamically regulated in the neurons and robustly modulate
synaptic excitability under physiological condition. Since NMDA receptors play a central role in synaptic
neurophysiology, plasticity, neuronal homeostasis, neurodevelopment as well as in the neurobiology of many diseases,
endogenous iron is therefore likely to have functional relevance to each of these areas.
Background
Although bio-available iron is essential for normal neuro-
logical function, iron deficiency or excess iron can produce
serious neurological consequences. Examples of CNS iron
misregulation associated with diseases include Friedreich’s
ataxia, associated with neuronal and myocardial mitochon-
drial iron accumulation [1, 2], Hallervorden-Spatz syn-
drome (defect on pantothenate kinase 2 - PANK2),
characterized by marked iron overload in the globus palli-
dus [3], aceruloplasminemia, generated by an iron overload
in basal ganglia [4], and Parkinson’s disease, where iron
accumulation is found in the substantia nigra [5]. Iron defi-
ciency both prenatally and perinatally have also been asso-
ciated with intellectual disabilities and psychiatric disorders
[6–9]. In each of these diseases, iron deregulation is
associated with the pathophysiology, yet it has been difficult
to assess a physiologic role played by iron in the brain.
However, lack of iron leads to impairment in hippocampal
electrophysiology, CA1 apical dendrite structure abnormal-
ity and deficits in learning and memory, indicating a
physiologic role for iron is present [10, 11].
To investigate iron modulation of neuronal physiology,
we focused on synaptic transmission and in particularly
the role of N-methyl-D-aspartate receptors (NMDA-Rs).
These are glutamate-gated ion channels widely expressed
in the central nervous system that play key roles at
glutamatergic transmission both within synapses and
extrasynaptically. Our prior data, as well as recent work
by others, demonstrate that extracellular iron can impact
NMDA-R dependent neurotoxicity [10, 12, 13]. We
showed that glutamate/NMDA neurotransmission modu-
lates neuronal iron trafficking via a small GTPase, Dexras1
[13, 14]. Following activation of neuronal Nitric Oxide
Synthase (nNOS), S-nitrosylation of Dexras1 by NO in-
duces iron transport via the Divalent Metal Transporter
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(DMT1) [13–15]. Thus we know that Dexras1 in complex
with DMT1 can transport extracellular iron across the cell
membrane [16, 17]. There are two isoforms of DMT1,
which are localized indifferent cellular compartments due
to differences in 20 amino acids at the C-terminus.
Localization studies revealed that isoform II has higher
cell surface expression and is efficiently sorted to recycling
endosomes upon internalization. By contrast, isoform I is
targeted to lysosomes [18]. A voltage clamp study showed
that each isoform has the same functional efficiency as an
iron transporter [19]. Thus, while prior work has focused
on the impact of extracellular iron, these studies targeted
a potential intracellular role for DMT1 that may be better
suited to modulate normal phUsing iron imaging in brain
slices, we first show that iron is available for signaling in
the hippocampus. Next, combining imaging and elec-
trophysiology we demonstrate that this intracellular
iron is sensitive to activity and that iron specifically
modulates NMDA-Rs to impact synaptic excitability.
Finally, we find that the Dexras1/DMT1 pathway in
lysosome is necessary to generate intracellular iron
signaling, and that disruption of the intact lysosomal
function impacts iron signaling. Together our findings
identify a novel iron signaling pathway with robust
affects on NMDA-R dependent excitability.
Results
Iron is released into the hippocampal cytosol in an
activity dependent manner
We have previously shown that neurotransmitter dy-
namically modulates trafficking of extracellular iron via
the plasma membrane in neurons leading to the excito-
toxicity [14]. What is less known is whether or how
cytosolic iron might affect the homeostasis of the excit-
ability of neurons. To investigate whether there is
detectable intracellular iron for signaling in the cytosol
of neurons we stained mouse hippocampal brain slices
with the heavy metal sensitive dye calcein-AM. Calcein-
AM passes through the plasma membrane and reacts
with cytosolic unspecific esterases producing calcein,
which is retained within the cytosol of cells. Calcein
fluorescence is quenched following chelation of low-
mass labile iron, as well as other polyvalent metals there-
fore it binds iron the most effectively at cytosolic pH
(despite its name it effectively binds to calcium or mag-
nesium only at alkaline pH) [20, 21]. To identify if there
was cytosolic iron in normal conditions, we measured
calcein de-quenching, or an increase in fluorescence,
following treatment of slices by a membrane permeable
iron chelator, 100 μM pyridoxal isonicotinoyl hydrazine
(PIH) [22–24] as combination of Calcein dye with an iron
chelator will provide iron specific fluorescent signal.
Following PIH application there was an increase in fluor-
escence in the CA1 region of the hippocampus (32 ± 6 %,
p < 0.001, n = 4 slices, Fig. 1a). This effect was only seen
with a membrane permeable iron chelator as neither non-
permeable iron chelator (deferioxamine) nor other divalent
metal chelators such as tetrathiomolybdate produce de-
quenching of calcein-AM (data not shown). Activation of
dissociated hippocampal neurons by 50 mM KCl also
quenched the calcein-AM signal while there is no change
in fluorescent signal in neurons from Dexras1 KO mice
suggesting an activity dependent release of iron into the
cytoplasm of the cell via Dexras1 (−77 ± 1.6 %; p < 0.0001,
n = 7) (Fig. 1b). Again supporting activity dependent iron
release the fluorescent signal was de-quenched by addition
of membrane permeable iron specific, chelator, PIH (89 ±
3.5 %, p < 0.0001, n = 7). In a previous study we have shown
that Dexras1-mediated iron flux is modulated by nNOS as
well as DMT1, an iron channel [16, 17]. Therefore we
pharmacologically blocked these enzymes utilizing L-
NAME (1 mM) or ebselen (10 uM) respectively and found
that an inhibition of either nNOS or DMT1 blocked iron
release into cytosol (Fig. 1c). To further validate these re-
sults, we measured a change in fluorescent signal utilizing
an alternative iron-sensitive dye, PhenGreen-SK, which is
composed of phenanthroline coupled to Flourescein [25,
26]. This dye like calcein-AM is insensitive to major intra-
cellular ions including endogenous levels of calcium. In this
experiment, we detected a signal with a 96 well fluores-
cence microplate reader and observed that the signal was
rapidly quenched upon neuronal cell depolarization sug-
gesting a rapid release of iron into cytosol (Fig. 1d).
Decreasing cytosolic iron pool enhances synaptic
excitability in the hippocampus
To investigate if the chelatable iron pool affects neuronal
excitability we studied the impact of iron chelation on
synaptic properties of CA1 pyramidal neurons. In hippo-
campal slices from wild type C57/B6 mice 100 μM PIH
application caused an increase in the frequency of spon-
taneous excitatory postsynaptic currents (EPSCs) (80 ±
14 %, p < 0.01, n = 16 cells, absolute values depicted in
Fig. 2a) without a change in either amplitude (17.5 ±
1.2pA vs 100 μM PIH: 18.8 ± 1.4pA, p > 0.3) or decay tau
(7.5 ± 0.5 ms vs 100 μM PIH: 7.8 ± 0.5 ms, p > 0.3).
Decay tau is defined as the time it takes for the signal to
return to baseline. In contrast to spontaneous EPSCs,
there was no increase in the frequency, amplitude or
decay tau of spontaneous IPSCs following PIH treatment
(Fig. 2a). Chelating iron also increases the evoked
response in a single cell to stimulation of the Schaffer
collaterals increasing EPSPs (Fig. 2b, 48 ± 17 %, p < 0.02,
n = 6 cells, individual experiments are depicted below).
Next to evaluate differences in the hippocampal circuit
response, population EPSPs were induced with a single
stimulation to the Schaffer collaterals, and the responses
recorded using voltage sensitive dye imaging (VSDi) at
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1 kHz. VSDi of hippocampal slices showed an evoked
fast depolarization that was followed by a rapid repolariza-
tion (Fig. 2c). Application of 100 μM PIH to a hippocampal
slice induced an increase in the evoked circuit EPSP re-
sponse (n = 10 slices). Both the amplitude and decay tau
were increased following PIH application (Fig. 2c, Amp: 30
± 4 %, p < 0.01; Tau: 75 ± 8 %, p < 0.001, n = 10, individual
experiments are depicted right). When only the vehicle of
PIH (5 μM NaOH) was applied to the bath no change in
excitability was detected in the slice (data not shown).
Moreover, we examined whether PIH treatment affects a
ternary complex among Dexras1, ACBD3 and DTM1 as a
formation of these complex is essential for Dexras1-
mediated iron flux and found that it is not (Fig. 3). Thus,
the whole cell and VSDi data show that when intracellular
iron is chelated there is an increase in excitability at the sin-
gle cell and circuit level of the hippocampus.
NMDA-Rs but not AMPA-Rs are necessary for iron’s effect
on evoked EPSP in CA1 of hippocampus
Since chelating iron affects the size of the evoked EPSP, we
next examined the role of NMDA and AMPA receptors in
the iron mediated regulation of hippocampal excitability.
Pre-incubation with 50 μM AP5, NMDA-R antagonist,
blocked the increase of spontaneous EPSCs induced by iron
chelation (Fig. 4a, n = 6 cells, absolute values are depicted
right). AP5 pre-incubation also blocked the increase in the
evoked EPSP (n = 5 cells individual cells are depicted in
Fig. 1 Liable iron is available in CA1 and is released in an activity
dependent manner. a. Following application of the iron sensitive
dye Calcein-AM, CA1 had the largest response to PIH application
when compared to DG and CA1 (n = 5). Top 2 panels show
pseudocolor images of hippocampal slices dyed with Calcein-AM
dye both before (left) and after 100 μM PIH (Right; an average of
15 s). Purple indicates the biggest change in fluorescence. Bottom
left shows the change in fluorescence over time normalized to
baseline fluorescence, and the bar graph is an average of the
change in fluorescence in CA1 and DG (*p < 0.05). b. Live cell
imaging was performed with primary hippocampal neurons using
fluorescence-based iron de-quenching imaging method with
Calcein-AM dye (n = 7). Depolarization of the neurons with 50 mM
KCl induces a 77 % decrease in fluorescence. When PIH is added to
the culture, fluorescence returns to 89 % of control (p < 0.001). In
contrast there is no decrease in fluorescence in Dexras1 KO
hippocampal cultures when PIH is applied. c. Summary of live cell
imaging with inhibitors which block nNOS and DMT1. Primary
hippocampal neurons are pretreated with inhibitors for 30 min and
an imaging experiment was performed as shown in Fig B. Inhibitor
treatment significantly reduced the iron released into the cytosol
(p < 0.05). d. Approximately 2,000 primary hippocampal neurons
were seeded in 96 well plates and labeled with PhennGreen SK dye
(20 μM). The fluorescent signal was measured by BioTek multiplate
reader linked with automated reagent dispenser for KCl (a final
concentration of 50 mM) (n = 3). The y-axis is arbitrary
fluorescence change
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Fig. 4b). NMDA-R receptor activity is also necessary for the
population responses examined by VSDi (Fig. 4c, Amp:
−0.14 ± 1.8 %, p = 0.7; Tau: 1.3 ± 1.4 %, p = 0.4, n = 5 slices,
values of individual experiments are depicted below). When
slices are recorded in the presence of AP5, PIH application
has no effect on the size of the VSDi eEPSP. In contrast,
changes in AMPA receptor activity does not contribute to
the iron chelation effect. When DNQX and Lo-Mg2+ is
present, PIH generates a larger increase in the amplitude
and decay tau of the EPSP (Fig. 4d, Amp: 35.2 ± 6 %, p <
0.01; Tau: 284.2 ± 26 %, p < 0.001, n = 5 slices, values of in-
dividual experiments are depicted right). When compared
to the increased seen when PIH is added to untreated wild
type slices, AP5 treated slices did not have an increase in
evoked VSDi EPSPs where DNQX treated slices has a simi-
lar percentage increase. (p < 0.05) (Fig. 4e). Confirming that
the increase in excitability was dependent on increased
NMDA-R activity we found that applying AP5 after a PIH
dependent increase in frequency immediately decreased the
EPSC frequency back to baseline (Fig. 5a and b, Control:
Fig. 2 Chelation of iron modifies the excitability of pyramidal cells and circuit of the hippocampus. a. Whole cell patch clamp of CA1 pyramidal
cells shows that 100 μM PIH application induces an increase in spontaneous EPSC frequency from 1.7 ± 0.28Hz to 2.8 ± 0.35Hz (*p < 0.05). On the
right, there is no change in IPSC with PIH. Top shows representative traces from an experiment and bottom are bar graphs of cumulative data.
b. There is an increase in the evoked EPSP in PIH. On the top is example recordings of whole cell current clamp and bottom is a graph showing
population (black) and average data (red) in the WT animals both before and after 100 μM PIH application. PIH causes an increase in the
amplitude of the evoked EPSP in CA1 pyramidal cells (Control: 3.7 ± 0.4 mV, PIH: 5.23 ± 0.4 mV, n = 6, p < 0.05). c. Shows grey scale image of a
hippocampal slice (on the left) and snapshots of peak responses to stimulation in control (middle) and 100 μM PIH (right) conditions (average of
30 ms). Underneath are the traces of an average response of pixel fluorescence signals over time from a standardized region of CA1 in both
conditions. There is an enhancement of the response following PIH application. Population line graphs of the VSD experiments as well as the
average (red) confirm that there is a consistent increase in both amplitude of EPSP and time to decay back to baseline (tau) (n = 10, *p < 0.05)
Fig. 3 Iron status does not affect a formation of ternary complex
among Dexras1/ACBD3/DMT1. Brain slices were treated with PIH as
described in Figs. 2 and 3. A treatment of tissues with PIH, iron
chelator did not change interaction between Dexras1, ACBD3
and DMT1
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0.9 ± 0.13Hz; PIH: 1.6 ± 0.29Hz; AP5 + PIH: 0.66 ± 0.19,
n = 5 cells).
Dexras1/DMT1 complex is necessary for the iron
dependent modulation of excitability
In neurons NMDA-mediated activation leads to Dexras1-
dependent iron transport via activation of neuronal nitric
oxide synthase (nNOS). Following NO dependent S-nitro-
sylation of Dexras1, the protein binds GTP and through its
link to a scaffolding protein, ACBD3, increases iron flux
through DMT1 [14]. Moreover, our data showed that gen-
etic or pharmacological inhibition of this pathway reduced
iron released into the cytosol (Fig. 1c). Hence, we hypothe-
sized that the Dexras1 complex is necessary to generate the
cytosolic iron leading to NMDAR-mediated modulation of
neuronal excitability. To investigate this role for Dexras1,
Fig. 4 Iron dependent regulation of hippocampal activation is
dependent on NMDA not AMPA. a. Shows an example of whole cell
recordings of WT slices during AP5 and AP5 + 100 μM PIH. Blocking
NMDA-R with AP5 abolishes the increase in spontaneous EPSCs. Bar
graph shows average of 6 experiments (Control: 2.6 ± 0.9Hz, PIH: 2.5 ±
0.9Hz, p= 0.85). b. AP-5 blocks or if anything reduces the PIH induced
increase in amplitude of the evoked VSDi EPSP (Control: 3.4 ± 0.7 mV,
PIH: 2.7 ± 0.7 mV, n= 5, p= 0.17). c. An example of a VSDi experiment
with AP5 treatment (left) and AP5 with 100 μM PIH added (right). The
NMDA-R antagonist AP5 blocks the increase in evoked VSDi EPSPs, as
shown by the representative traces underneath the snapshots of peak
responses. d. VSDi analysis of evoked EPSP in the presence of the DNQX
(AMPA and kainate receptor antagonist) in low Mg2+ ACSF, which are
conditions favoring NMDA activity (left) and DNQX with PIH on the right.
Blocking AMPA and kainate receptors does not have an effect on the
VSDi eEPSP. e. Blocking NMDA receptors causes PIH to no longer be able
to increase the VSDi eEPSP. However only blocking AMPA receptors still
allows for an increase in VSDi eEPSP size (p< 0.05). WT data is shown
for comparison
Fig. 5 NMDAs R regulate the increase in sEPSC following PIH
application. a. Adding AP5 to the bath after PIH application causes sEPSC
frequency to return to baseline. This shows snap shots of whole cell
recordings during initial control (no drug), PIH application, and then AP5
in addition to 100 μM PIH (n= 5). b. Quantification of sEPSC frequency
during PIH and PIH with AP5 normalized to control frequency before
any drug application. There is a decrease in EPSC frequency back to
baseline after AP5 is added to the bath (n= 5 *p< 0.05
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we performed the same iron chelation experiments on Dex-
ras1 knock out (DexKO) animals. Whole cell patch clamp
experiments showed that there were no baseline differences
in neuronal excitability as measured by membrane poten-
tial, current input–output curve and baseline spontaneous
EPSCs. Unlike the wild type mice there was no significant
change in sEPSC frequency in DexKO animals when iron is
chelated (Fig. 6a, n = 8, p = 0.13,). Evoked EPSPs were also
unaffected in DexKO animals as PIH application had no
effect on EPSP amplitude (Fig. 6b, n = 6, p > 0.05). PIH
application in the KO mice caused a much reduced
increase on the circuit EPSP when measured by VSDi; an
example of this experiment is shown in Fig. 6c (8.4 ± 1.5 %
n = 4, p < 0.02), but a decrease in the decay tau (−15.3 ±
3.3 % n = 4, p < 0.02,). This increase was a third less than
the PIH increase of the evoked circuit EPSP found in WT
animals (p < 0.01), suggesting that Dexras1 is required for
iron dependent NMDAR-mediated modulation of neuronal
excitability (Fig. 6d). To directly test signaling through the
Dexras1 complex, we performed VSDi experiments while
blocking the nitric oxide (NO) pathway as previous
studies have shown that NO activation is necessary
for Dexras1 to stimulate iron transporter, DMT1 [13,
14]. When the NO pathway was blocked using L-
NAME (nitric oxide synthase inhibitor) chelating iron
with PIH no longer induced an increase evoked cir-
cuit EPSP, if anything a decrease (n = 4, p = 0.14) how-
ever the tau of decay was increased (Fig. 7a, 22.3.4 ±
0.56 %, p < 0.01, n = 4). We next blocked DMT1 using
the small molecular DMT1 transport inhibitor, ebse-
len, which completely blocked the PIH effect (Fig. 7b,
1.1 ± 2.4 %, p = 0.81, n = 3). Blocking the proteins as-
sociated with the Dexras1 pathway, NO pathway and
DMT1, also blocks the increase in VSDi evoked
EPSP (Fig. 7c) These data demonstrate that NMDA-
R activity is affected by intracellular iron and the
same iron-signaling pathway that mediates NMDA
neurotoxicity is involved in regulation of cellular ex-
citation, with normal levels of iron likely reducing
NMDA-R activity and chelating iron increasing it.
Fig. 6 Iron chelation dependent increase in excitability is dependent on Dexras1. a. Whole cell patch clamp in Dexras1 KO animals show that
there is no effect of chelation on CA1 excitability. PIH has no effect on the frequency of EPSCs in CA1 neurons in Dexras1 KO animals (Control:
1.4 ± 0.3 Hz, PIH: 1.2 ± 0.1 Hz, n = 8, p = 0.13). PIH application does not increase VSDi eEPSP sized in Dexras KO despite using Low Mg2+ ACSF.
b. Whole cell patch in pyramidal cells of Dexras1 KO also show no increase in evoked EPSPs when PIH is applied On the top is example
recordings of whole cell current clamp and bottom is a graph showing population (black) and average data (red) in the WT animals both before
and after 100 μM PIH application (Control: 10.0 ± 2.6 mV, PIH: 8.8 ± 2.3 mV, n = 8, p = 0.27). c. VSDi analysis of Dexras1 KO animals shows that PIH
has no effect on the evoked response. An example of a VSDi experiment with Dex KO slices control (left) and with 100 μM PIH added (right).
Directly underneath are average responses averaged over 30 ms post stimulus. d. Knocking out Dexras1 causes PIH to no longer have an effect
on VSDi eEPSP size
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Iron reduction modulates NMDA-Rs via SRC signaling
Our data showed that chelatable iron pool modulates
NMDA-R function and NMDA-R dependent excitability
under physiological condition. It has been well docu-
mented that NMDA-R function is regulated by Src
kinase [27]. Therefore, we first examined whether a
50 μM PIH treatment has any effect on Src signaling.
We observed that acute iron chelation in hippocampal
slices dramatically increases the levels of phospho-Src
(Y416) as well as the levels of NR2A (Fig. 8a). These
changes were mediated by the Dexras1 pathway as a
deletion of Dexras1 abolished iron chelation-induced
phosphorylation of Src (Fig. 8b). Previous data (Fig. 1c)
showed that NOS or DMT1 inhibitors blocked iron
release into cytosol. Hence we examined whether these
agents can reduce pSrc activity. Protein kinase C (PKC)
is known to be sensitive to iron levels and is an
upstream of Src, through which it also is known to regu-
late NMDA-R [27]. Treating hippocampal slices with
50 μM PIH in the presence of PKC inhibitor, Calphostin
C (10 μM) significantly attenuated PIH-mediated activa-
tion of Src and NR2A expression (Fig. 8c). Moreover,
we examined whether an inhibitor of nNOS and
DMT1 (L-NAME and ebselen, respectively) has any
effect on pSrc, NR2A and PKC. We fund that these
treatments significantly reduced expression levels of
NR2A and pSrc, and activities of PKC (Fig. 8d and e).
These experiments demonstrated that the Dexras1
dependent modulation of iron regulates NMDA excit-
ability via PKC/Src signaling.
The Dexras1 complex is present at the lysosomal
membrane
Unlike prior studies of NMDA and iron-dependent neur-
onal cell death, in these experiments extracellular iron was
not added to the extracellular medium nor was a mem-
brane impermeable chelator able to generate the increased
neuronal excitability found with PIH indicating that an
intracellular source of iron is needed. The lysosome seems
well suited to be such a source. A considerable amount of
the iron pool can be found in the lysosome [28]. Recent
findings from patch-clamping of individual lysosomes show
that they can transmit iron through their membrane [29].
Finally, DMT1, which is located on both endo-lysosomal
and extracellular membranes, functions more efficiently as
a transporter when the pH is low (~5) [30] and the DMT1-
isoform 1, which is primarily localized in lysosome, is highly
expressed in hippocampus [15, 18]. To examine if the
Dexras1 complex with DMT1 is indeed present at the lyso-
some we isolated lysosomal and cytosolic fractions and
tested for Dexras1 and the associated scaffolding protein
ACBD3, finding that both Dexras1 and ACBD3 are present
in the lysosome. Importantly, ACBD3 knockdown by RNAi
significantly reduced a level of Dexras1 associated with a
Fig. 7 The NO pathway and DMT1 (components of the Dexras1
pathway) are necessary for iron to effect neuronal excitability. a. Blocking
the NO pathway blocks the PIH induced increase in VSDi eEPEP. An
example of a VSDi experiment with L-NAME treatment (left) and L-NAME
with 100 μM PIH added (right). The NO pathway antagonist blocks the
increase in evoked VSDi EPSPs, as shown by the representative traces
underneath the snapshots of peak responses and population data on
the right. (Amp: L-NAME: 1.3x10−3 ± 0.1x10−3 %ΔF/Fo, PIH: 1.2x10−3 ±
8.3x10−5 ΔF/Fo, n= 4, p= 0.15). b. Blocking DMT1 with ebselen also
blocks the PIH induced increase in VSDi eEPEP. An example of a VSDi
experiment with ebselen treatment (left) and ebselen with 100 μM PIH
added (right). The DMT1 antagonist blocks the increase in evoked VSDi
EPSPs, as shown by the representative traces underneath the snapshots
of peak responses and population data on the right (Amp: ebselen:
4.6x10−3 ± 0.5x10−3 %ΔF/Fo, PIH: 4.6x10−3 ± 0.4x10−3 ΔF/Fo, n= 3,
p= 0.8). c. Blocking the NO pathway with L-NAME or blocking DMT1
with ebselen, cause PIH to no longer be able to increase the VSDi eEPSP
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lysosomal fraction (Fig. 9a) suggesting that Dexras1 is local-
ized in lysosome via ACBD3. Additionally, confocal im-
aging analysis revealed that ACBD3 is highly co-localized
with LAMP-2, a lysosomal marker, corroborating that a
ternary complex of Dexras1/ACBD3/DMT1 can be formed
on the lysosome (Fig. 9b).
After establishing that the elements of the Dexras1/
DMT1 complex are at the lysosome, we investigated
whether the lysosome is involved in the iron signaling.
We disrupted lysosomal function using 5 mM NH4Cl, to
compromise the pH gradient and examined the presence
of cheatable iron in CA1, the ability of PIH to increase
excitability and Src phosphorylation. As shown in Fig. 9c
we found that collapsing the proton gradient reduced
the PIH-induced change in fluorescence in calcein-AM
dye signal as similar to the treatment with ebselen1,
which blocks DMT1 channel. In the VSDi experiments
NMDA EPSPs were isolated pharmacologically limiting
the impact of NH4Cl to NMDA excitability. Because
5 mM NH4Cl can impact hippocampal excitability itself,
it is important that under these conditions, baseline
responses in ACSF containing NH4Cl did not appear
different from untreated slices. Under these conditions
PIH did not increase excitability (Fig. 9d, −19.3.4 ±
2.7 %, p = 0.21, n = 6 slices, individual experiments are
graphed right). We further confirmed that bafilomycin, an
inhibitor of lysosomal function also reduced PIH-mediated
ESPS (Fig. 9e; NH4Cl: −19 ± 2.7 % n = 6, p > 0.2; 1 μM Bafi-
liomycin: 12 ± 10 % n = 8, p > 0.2). Slices treated with
NH4Cl also lost iron chelator-mediated activation of Src
Fig. 8 Dexras1-mediated iron flux modulates phosphorylation of
NR2A via PKC-Src pathway. a. Phosphorylated Src is increased
following treatment with PIH. Brain slices from WT mice were treated
with 50 μM PIH for 15 min and various proteins were quantified via
western blot analysis. ARC, an immediate early gene and important
signaling molecule in synaptic plasticity, is elevated as well as pSrc
but not unphosphorylated total Src. The bottom band is the internal
control GAPDH. b. Western blot analysis of brain homogenates show
that there are differences in NR2A protein expression between WT
and Dexras1 knockout mice and that there is a decrease in the
baseline level of phosphorylated pSrc (n = 4). PIH application does
not induce phosphorylation of Src. The bottom band is the internal
control GAPDH. c. Hippocampal slices were pre-treated with
calphostin C (10 μM) for 15 min and followed by 15 min PIH
treatment. Western blot analysis show that calphostin C treatment
blocks PIH-mediated activation of pSrc and NR2A. The bottom band
is the internal control GAPDH. d. Hippocampal slices were
pre-treated with either L-NAME (1 mM) or Ebselen (10 uM) for
15 min as described in Fig. 6 and followed by 15 min PIH treatment.
Western blot analysis show that these treatments blocks
PIH-mediated activation of pSrc and NR2A. The bottom band is the
internal control GAPDH. e. Iron chelatrion increased PKC activity
while inhibition of nNOS or DMT1 blocked PIH-mediated activation
of PKC. Brain slices from WT mice were pretreated with either
L-NAME or Ebselen and subsequently treated with PIH as described
above. Tissues were lysed and PKC activity was measured
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(Fig. 9f). These data are consistent with the hypothesis that
an intact lysosome is required for the intracellular iron flux
modulating NMDA dependent neuronal excitability.
Disscusion
In this paper we have demonstrated that intracellular
iron signaling can modulate neuronal excitability in
the hippocampus. We show that iron is released in
neurons when stimulated either by KCl or via synap-
tic stimulation and in turn, this release can regulate
neuronal excitability. When intracellular iron is re-
duced, Schaffer evoked synaptic responses in CA1 as
well as spontaneous EPSCs were increased. NMDA-R
and kinase pathways controlling NMDA-R activity
were necessary for this rapid increase in excitability.
By extension it is likely that iron acts to suppress
NMDA-R dependent excitability in response to exci-
tation. The small GTPase Dexras1 and its associated
partners including the metal transporter DMT1 were
also necessary for the iron-mediated regulation of
excitability. In contrast to conditions leading to cell
death, physiological levels of iron appear to suppress
NMDA dependent changes in excitability and thus
iron at physiological levels may limit the potential
for excitotoxicity.
Lack of extracellular iron or cell impermeable chelators
had no impact on excitability, indicating that intracellular
release is sufficient to dampen these changes in excitabil-
ity. Our studies point to the lysosome as the most likely
source of the intracellular iron flux. The Dexras1 complex
is present at the lysosome and when the lysosomal proton
gradient is collapsed chelatable iron is reduced and the
chelation-dependent increase in excitability is lost. To-
gether these data chart a pathway where intracellular iron
released from intracellular stores regulates neuronal excit-
ability by decreasing NMDA receptor mediated excitation
of pyramidal neurons in the hippocampus (Fig. 10).
NMDA-R dependent increase in spontaneous EPSCs
One of the most robust findings was an iron chelation
dependent increase in spontaneous EPSCs frequency. At
first we saw this increase in frequency as likely due to a
separate non-NMDA-dependent presynaptic effect of iron
Fig. 9 Lysosomes are the source of iron involved with regulating
NMDA-R function. a. Lysosomal subcellular fraction was isolated and
immunoblotted for ACBD3 and Dexras1. Lysosomal specific marker
(Rab7) was only detected in the lysosome fraction (L) but not in the
cytoplasm fraction (C). b. Confocal image shows that ACBD3 is
co-localized to lysosome marker LAMP-2. c. In Calcein-AM treated
slices, PIH is able to de-quench Fe2+ from Calcein in CA1, and this
effect is blocked by the DMT1 antagonist 10 μM ebselen and as well
as 5 mM NH4Cl, which collapses the lysosome proton gradient.
d. VSD imaging of CA1 shows that there is no increase in response
to stimulation following PIH application when the lysosome is
perturbed with NH4Cl. To the right is an averaged response of pixel
intensities over time from a standardized region of CA1 in both
Control (black) and PIH (red). e. There is no enhancement of the
response following PIH application when slices are incubated with
NH4Cl,(n = 6 slices; (p = 0.4) of with Bafilomycin, which also perturbs
lysosomal release of iron (n = 9; p = 0.21). f. Western blot analysis of
brain homogenates before and after PIH treatment when the brains
were pre-incubated with NH4Cl. Collapsing the lysosomal proton
gradient abolishes the phosphorylation of Src
Fig. 10 Iron Modulates NMDA-R function via Src and PKC pathway
which then mediates neuronal excitability. NMDA-mediated activation of
Dexras1 modulates iron release from intracellular source, lysosome via
iron transporter, DMT1 and this consequently suppresses synaptic NMDA
activity by suppressing PKC/Src pathway. Therefore, Dexras1-mediated
iron modulation in neurons can act in a feedback manner to modulate
NMDA function and thus may exert homeostatic control of excitability
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chelation. However, the ability of the NMDA-R antagonist
AP5 to block, as well as reverse the PIH dependent in-
creases in frequency again demonstrated a central role for
NMDA-R. The best explanation is reflected in a presynaptic
NMDA-R role in modulating spontaneous release found
through recordings of miniature (action potential inde-
pendent) EPSCs or spontaneous EPSCs [31, 32]. In Kunz
et al. disrupting intracellular calcium signaling increased
frequency, but not amplitude of mEPSCs, as in our work
this frequency increase could be reversed by AP5 [31].
Thus, while our studies target different intracellular
messenger systems, our results converge on presynaptic
NMDA-Rs to modulate spontaneous synaptic release.
Sources of iron in the neuron
Iron is abundant in the brain [33] and yet most of the
studies of iron functionality in the brain have centered on
its pathophysiological properties as a catalyst in the pro-
duction of ROS that contribute to neurodegeneration [34].
A more physiological role of iron is known to regulate the
activities of enzymes that control the synthesis of neuro-
transmitters, and in particular catecholamines [33, 35]. A
lack of iron leads to aberrant neuronal activities, such as
impairment in hippocampal electrophysiology, disrupted
CA1 apical dendrite structure, and deficits in learning and
memory [10, 11]. These observations suggest that iron in
the brain may play a role in signaling. Physiologically, the
majority of cells in the body acquire iron from a well-
characterized plasma glycoprotein by receptor-mediated
endocytosis through the transferrin receptor. Any excess
iron delivered to the cytoplasm is transported to a storage
protein, ferritin [16, 36–38], which is recycled by lyso-
somes [28, 39]. Previous literature suggested that iron in
ferritin can be released, but this process is extremely slow
because iron is in a mineralized form. Thus, ferritin bound
iron likely has little contribution to the intracellular iron
described in the results [40, 41]. However, that ferritin is
degraded in the lysosome [38, 39, 42]. When this happens
the iron is released where iron’s solubility is aided by the
acidic environment of the lysosome. While there are very
few studies investigating the mechanism by which lyso-
somal iron is recycled, it has been reported that iron can
be also released from lysosome via type IV mucolipidosis-
associated protein TRPML1 [29]. Therefore, our data and
current literature strongly support the notion that lyso-
somal iron may be a source for a bio-active iron, which
can be immediately utilized for physiological functions.
Dexras1 complex at the lysosome
Interestingly, DMT1-isoform I, which is primarily tar-
geted to the lysosome, is highly expressed in the hippo-
campus, where we observed a significant presence of
intracellular iron. We also determined that the Dexras1/
ACBD3/DMT1 ternary complex appears present on the
lysosome. Thus, our current studies further extend the
role of Dexras1 as a modulator of intracellular iron and
broaden the possible roles of this intracellular source of
iron. In fact, DMT1 may be better able to play a role in
ferritin iron recycling from lysosome [39, 41], since iron
flux activity of DMT1 is several folds higher at low pH.
Potentially confounding metals
It is prudent to mention that DMT1 can transport
other various metals such as Cu, Zn or Mn and as in
any similar studies our dyes and chelators can also
bind other metals, generating potential confounds.
Moreover, it has been shown that Cu as well as Mn can
inhibit NMDA–R function. Yet, the Ki values of these
metals are above 100 μM, which are levels usually only
reached under pathological or experimental conditions
[43]. We have further excluded a possibility of Cu, as
the Cu-chelator, tetrathiomolybdate, did not mimic the
effect of iron chelation. Zn has also been extensively
studied in neurological system, impacts NMDA-R
activity and is involved in the most established metal
signaling mechanisms in the brain [44–49]. We can
speculate that Zn-released from lysosome may explain
our observations as DMT1 can transport Zn. However,
it is unlikely that Zn is playing a role in our data. First,
the chelator we utilized, PIH, is selective for iron over
Zn [22]. Secondly, Zn containing neurons are exten-
sively concentrated in the dentate gyrus and mossy
fibers that innervate CA3 [50] and our imaging data
detected the greatest concentration of cheatable metal
in hippocampal area CA1. Moreover, Zn is known to
predominantly inhibit NMDA-R function by directly
binding to the receptor at an extracellular domain [51]
and the increased in NMDA-R dependent EPSPs was
only generated by membrane permeable chelators.
Because vesicular Zn is present in area CA1 and intra-
cellular Zn can act on the post-synaptic scaffolding
proteins, a role of Zn cannot completely be ruled out,
though intracellular Zn acting on PKC has not been
reported [52]. Thus, intracellular iron released from
lysosome remains the most likely candidate for intra-
cellular metal dependent modulation of NMDA-R
function, highlighting a novel form of metal signaling
within the cell.
Role for Dexras1 complex and iron on NMDA-R activity
This work finds that reducing iron can enhance NMDA-R
excitability, via PKC and Src dependent signaling. This is
consistent with prior work that iron chelation can activate
the PKC pathway in other tissue [53, 54]. As recent litera-
ture suggests this change in PKC activity may be through
ROS associated with iron, which can be potent signaling
molecules [55–57]. ROS generation can indeed impact
NMDA-R function and our data may elucidate a
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molecular signaling pathway in which NMDA-mediated
re-distribution of iron can precisely control the NMDA-R
function through ROS generation. Together, the prior
work demonstrating a Dexras1 and NMDA dependent
increase in iron, and the present study illustrating how
Dexras1 dependent iron release my suppress NMDA
activity, indicates that Dexras1 signaling and iron can act
in a feedback manner to modulate NMDA function and
thus may exert homeostatic control of excitability. Add-
itionally, the potential feedback role of this mechanism
may explain the phenomena of NMDA dependent pre-
conditioning where low levels of NMDA-R activity can
reduce later NMDA dependent excitotoxic damage in
models of neurodegeneration [13, 14].
In identifying a unique target for modulating NMDA-
R, we in turn potentially target a host of neuronal func-
tions dependent on NMDA-Rs. In fact, this pathway
may suggest a novel mechanism of action for the DMT1
channel blocker, ebselen, which has shown promise as a
replacement for psychiatric uses of lithium [58]. The
physiological significance of iron acting on NMDA-R
activity is heightened by robust affects on both pre and
post-synaptic excitability. Because NMDA-R activity in
area CA1 and other parts of the brain mediates homeo-
stasis, development and plasticity central to learning and
memory mechanisms, iron modulation of NMDA-R
activity through the Dexras1 dependent pathway may be
an important component of these processes. The current
establishment of this molecular pathway and the impact
of iron on NMDA dependent synaptic excitability sets
the stage for targeting iron and the Dexras1 pathways in
learning and other behaviors.
Conclusions
We found that genetic and pharmacological ablation of
this pathway increased glutamatergic transmission. Volt-
age sensitive dye imaging of hippocampal slices and
whole-cell patch clamping of synaptic currents, indicated
that the increase in excitability was due to synaptic modi-
fication of NMDA-R activity via modulation of the PKC/
Src/NR2A pathway. Moreover, we identified that lyso-
somal iron serves as a main source for intracellular iron
signaling modulating NMDA-R mediated glutamatergic
excitability. These data reveal a unique intracellular role of
iron to robustly modulate synaptic excitability under
physiological conditions of iron in neurons.
Methods
Animals
All animals (wild type “male” C57BL/6 and Dexras1/
RASD1 KO) were housed 4–5 per cage on a 12-h light/
dark cycle in a temperature-controlled facility with food
and water available ad libitum. All experiments were
performed during their light cycle when they were 2–6
month of age. All protocols for their care and testing
were performed in accordance with University Labora-
tory Animal Resources guidelines and approved by the
Institutional animal Care and Use Committee. Dexras1/
RASD1 knock out animals were genotyped with PCR as
explained in [13].
Pharmacological agents
50–100 μM pyridoxal isonicotinoyl hydrazone (PIH), a
membrane permeable iron chelator, dissolved in 5 mM
NaOH (final concentration 5 μM) was used in most of
the following experiments to chelate iron. 50 μM (2R)-
amino-5-phosphonopentanoate (AP5), was used to block
NMDA-R and 50 μM 6, 7-dinitroquinoxaline-2, 3-dione
(DNQX), was used to block AMPA and Kainate recep-
tors. 10 μM ebselen was used to block divalent metal
transporter 1 (DMT1). One mM L-NAME was used to
block the nitrous oxide synthase pathway. To collapse
the lysosomal proton gradient 5 mM NH4Cl was applied
in the ACSF.
Single cell iron imaging
Primary hippocampal neurons were prepared as described
before [14, 59]. Cells were washed with warm PBS (×2)
and incubated with 20 μM Calcien-AM (Inivtrogen) for
30 min in PBS. Cells were washed with Kreb’s buffer
(118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 4.2 mM NaHCO3, 2 mM CaCl2, 10 mM glucose,
200 mM sulphinpyrazone and 10 mM Hepes, pH 7.4)
twice. Cells were placed in 1 mM Kreb’s buffer containing
50 mM KCl and immunofluorescence was measured by
LEICA TCS SP5 confocal microscope (excitation 495 nm,
emission 515 nm). Five to ten minutes later, 100 μM of
PIH was added into buffer and fluorescence signal was
measured.
Transverse hippocampal slice iron imaging
Mice between 3 to 4 weeks-old were decapitated follow-
ing brief isoflurane anesthesia. The brain was removed
and transverse slices (350 μm) containing the hippocam-
pus were cut with a vibratome in an ice-cold artificial
cerebrospinal fluid solution (ACSF), in which NaCl was
replaced by an equiosmolar concentration of sucrose.
ACSF consisted of 130 mM NaCl, 3 mM KCl, 1.25 mM
NaH2PO4, 26 mM NaHCO3, 10 mM glucose, 1 mM
MgCl2, and 2 mM CaCl2 (pH 7.2–7.4 when saturated
with 95 % O2/5 % CO2). Slices were incubated in ACSF
at 32–34 °C for 30 min and kept at 22–25 °C thereafter,
until transfer to the recording chamber. The osmolarity
of all extracellular solutions was 305–315 mOsm. Slices
were viewed using infrared differential interference con-
trast optics under an upright microscope (Eclipse FN1,
Nikon Instruments) with a 40 ×water-immersion objective.
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Electrophysiology
Voltage sensitive dye imaging
Two month old wild type and dexras1−/− (DexKO) mice
were decapitated following isoflurane anesthesia. The brain
was removed and horizontal hippocampal slices (350 μm)
were cut with an Integraslice 7550 PSDS (Campden Instru-
ments, Lafayette, IN) in an ice-cold artificial cerebrospinal
fluid (ACSF) containing an equiosmolar concentration of
sucrose. Recording Na-ACSF consisted of: 130 mM NaCl,
3 KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM
glucose, 1 mM MgCl2, 2 mM CaCl2 (pH 7.2–7.4 when
saturated with 95 % O2/5 % CO2). Hippocampal slices (be-
tween −5.60 and −6.60 from Bregma) were then transferred
to a static interface chamber (34 °C) for 30 min and kept at
22–25 °C thereafter, until transfer to the recording cham-
ber. The osmolarity of all solutions was 305–315 mOsm.
To focus on NMDA dependent synaptic activity, many
experiments (DexKO and NH4Cl VSDi conditions) were
done with a Lo-Mg2+ ACSF, which consisted of: 130 mM
NaCl, 3 mM KCl, 1.1 mM NaH2PO4, 26 mM NaHCO3,
10 mM glucose, 0.1 mM MgCl2, and 2 mM CaCl2
(pH 7.2–7.4 when saturated with 95 % O2/5 % CO2) in the
presence of DNQX.
Slices were stained with 0.125 mg/ml of the voltage-
sensitive dye di-3-ANEPPDHQ (D36801, Invitrogen) in
ACSF for 20 min, and imaged in an oxygenated interface
chamber (34 °C) using an 80 × 80 CCD camera recording
at a 2-kHz frame rate (NeuroCCD: RedShirtImaging,
Decatur, GA). Epi-illumination was provided by a custom
LED illuminator. Compared with the more commonly
used photodiode array, the CCD chip well size (215,000
electrons) requires use of relatively low light intensities
minimizing photodynamic damage. A 10 × objective lens
(Olympus, Tokyo, Japan) imaged a 2.5 × 2.5 mm CA1
region (32 × 32 μm region per pixel). Schaffer collateral
stimulation was administered with the electrode placed
near the border of CA1 in the stratum radiatum (SR).
Each trial consisted of 12 stimuli, 20 μs apart.
Whole-cell patch recording
A recording chamber for submerged brain slices was
continuously perfused (1–2 ml/min) with oxygenated ACSF
heated to 32 ± 1 °C using an automatic temperature con-
troller (Warner Instruments). Recording pipettes were
pulled from borosilicate glass capillaries (World Precision
Instruments) to a resistance of 3–7 MΩ when filled with
the intracellular solution. For voltage clamp and spontan-
eous PSC recordings, the intracellular solution contained:
145 mM potassium gluconate, 2 mM MgCl2, 2.5 mM KCl,
2.5 mM NaCl, 0.1 mM BAPTA, 10 mM HEPES,
2 mM Mg-ATP, 0.5 mM GTP-Tris, and 5 mM QX-314
(pH 7.2–7.3 with KOH, osmolarity 280–290 mOsm).
Evoked PSCs and Spontaneous PSC recordings were con-
ducted in whole-cell voltage-clamp mode (Vh =–70 mV for
spontaneous EPSCs and Vh = 0 mV for spontaneous
IPSCs). All recordings were conducted with a Multi-
Clamp700B amplifier (Molecular Devices). Currents were
low-pass filtered at 2 kHz and digitized at 20 kHz using a
Digidata 1440A acquisition board and pClamp10 software
(both from Molecular Devices). Access resistance (10–30
MΩ) was monitored throughout the recordings by injec-
tion of 10 mV hyperpolarizing pulses and data were dis-
carded if access resistance changed by >25 % over the
course of data acquisition. Evoked responses were triggered
by 100 μs constant-current pulses generated by an A310
Accupulser (World Precision Instruments) and delivered at
0.1 Hz via a bipolar tungsten stimulation electrode posi-
tioned within 100 μm of the recorded cell. The amplitude
of the current pulses was controlled by a stimulus isolator
(ISO-Flex, AMPI) and was adjusted to elicit monosynaptic
responses in the range of 50–300 pA.
Ex vivo stimulation and immunoblotting
Hippocampi from mice were cut at 350 μM intervals in
sagittal and coronal planes using a McIlwain tissue chop-
per. The slices were dispersed in oxygenated artificial cere-
brospinal fluid buffer (ACSF, 113 mM NaCl, 4.5 mM KCl,
1 mM MgCl2, 25 mM NaHCO3, 1 mM NaH2PO4, 25 mM
Glucose, 2 mM CaCl2) and then incubated with reagents
(Sigma, St. Louis, MO) for 15 min and washed with ice
cold ACSF [60, 61]. Tissues were lysed in lysis buffer and
subjected to SDS-PAGE and immunoblot, as previously
described [13, 61, 62–64] Antibodies for NR2A, pSRc
(Y416), Src with GAPDH as a loading control were from
Cell Signaling, (Danvers, MA) and Arc antibody is from
Santa Cruz Biotechnology (Santa Cruz, CA).
Cellular fractionation
Lysosome fractions were isolated by lysosome enrichment
kit for tissue and cell culture from Thermo Scientific ac-
cording to manufacturer’s instruction.
Immunofluorescence
PC-12 cells were seeded on glass cover-slips as described
before [62]. LAMP2 and ACBD3 antibody were purchased
from Abcam (Eugene, OR). Bound antibodies were visual-
ized using Alexa Fluor 594 goat anti-mouse IgGs and 488
goat anti-rabbit IgGs (Invitrogen). Confocal microscopy
analysis was performed under oil immersion on Leica
DMI6000 (Leica Microsystems) with a 63× objective [62].
Abbreviation
ACBD3: acyl coa binding domain 3; AMPA: α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; DexKO: Dexras1 knock out; DMTA: divalent metal
transporter 1; EPSC: excitatory postsynaptic currents; IPSC: inhibitory
postsynaptic currents; NMDA: N-methyl-D-aspartate, NMDA; nNOS: neuronal
nitric oxide synthase; NO: nitric oxide; NR: NMDA receptor; PC12: adrenal
pheochromocytoma; PIH: pyridoxal isonicotinoyl hydrazine; PKC: protein
kinase C; VSDi: voltage sensitive dye imaging.
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